ReviewTrends in microbiology2023
Modes of therapeutic delivery in synthetic microbiology.
Review in Trends in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Adhesion-Enhanced Engineered Probiotic for Prolonged Intestinal Retention and Calprotectin-Responsive IBD Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Programmable genetic control of tumor-colonizingbioRxiv : the preprint server for biology · 2026Article
- A standardized toolkit for programmable protein secretion and surface display inbioRxiv : the preprint server for biology · 2026Article
- Small regulatory RNAs modulate lactococcal susceptibility to cell wall-targeting antimicrobials.Nucleic acids research · 2026Article
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Temperature-Dependent Recombinase-Based Genetic Circuits.International journal of molecular sciences · 2025Article
- Review
- Repurposing the bacterial surface display technology for drug delivery.Advanced drug delivery reviews · 2025Review
- Microbial membrane vesicles and the intestinal epithelium: a crosstalk in health and disease.Archives of microbiology · 2025Review
- Smart closed-loop drug delivery systems.Nature reviews bioengineering · 2025Article
- Limosilactobacillus reuteri enables oral-to-systemic absorption of iberiotoxin for treatment of collagen-induced arthritis in rats.Microbial cell factories · 2025Article
- Genetic "expiry-date" circuits control lifespan of synthetic scavenger bacteria for safe bioremediation.Nucleic acids research · 2025Article
- Odoribacter splanchnicus-A Next-Generation Probiotic Candidate.Microorganisms · 2025Review
- Bioengineered Probiotics for Clostridioides difficile Infection: An Overview of the Challenges and Potential for This New Treatment Approach.Probiotics and antimicrobial proteins · 2025Review
- Harnessing the Human Microbiome for Innovative Drug Delivery Systems: Exploring Pharmacomicrobiomics and Targeted Therapies.Current pharmaceutical design · 2025Review
- Combinatorial leaky probiotic for anticancer immunopotentiation and tumor eradication.Cell reports. Medicine · 2024Article
- Synthetic Biology-Driven Microbial Therapeutics for Disease Treatment.Journal of microbiology and biotechnology · 2024Review
- Growth phase matters: Boosting immunity via Lacticasebacillus-derived membrane vesicles and their interactions with TLR2 pathways.Journal of extracellular biology · 2024Article
- Human and animal intestinal commensals and probiotics vs modern challenges of biosafety: problems and prospects.Archives of Razi Institute · 2024Review
- The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.Virology journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
For decades, bacteria have been exploited as vectors for vaccines and therapeutics. However, the bacterial arsenal used has historically been limited to a few strains. Advancements in immunology, combined with the development of genetic tools, have expanded our strategies and capabilities to engineer bacteria using various delivery strategies. Depending on the application, each delivery strategy requires specific considerations, optimization, and safety concerns. Here, we review various modes of therapeutic delivery used to target or vaccinate against a variety of ailments in preclinical models and in clinical trials. We highlight modes of bacteria-derived delivery best suited for different applications. Finally, we discuss current obstacles in bacteria-derived therapies and explore potential improvements of the various modes of therapeutic delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.